GoAI
Get started
Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc.

TPST

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$1.05

+$0.02 · +1.96%

Aug 21, 3:55 PM ET

TPST company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

25

Expensive

Momentum

20

Strong Down

Sentiment

47

Mixed

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Matthew Angel
Listed since
Nov 12, 2012
Employees
4

Market position

Volume
133.86K
0.67× average
Average volume
199.99K
Average daily volume
Market cap
16.62M USD
Beta
-1.68
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
12.34M USD
P/E (TTM)
-0.23×
P/B (TTM)
-14.53×
P/S (TTM)
0×
EV / EBITDA
-0.48×
Earnings yield
-220.51%
Free cash flow yield
-225.19%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-393.85%
Return on assets
-155.11%
Return on invested capital
-179.45%

Financial health

Debt / equity
-6.94×
Current ratio
2.5×

Financial statements

Income trends

Operating income

−26.58M USD+36.77%

Net income

−26.26M USD+37.24%
Income trends across reported periods−24.69M USD−30.99M USD−37.3M USD−43.6M USDOperating income, FY2021: −26.99M USDOperating income, FY2022: −34.64M USDOperating income, FY2023: −29.16M USDOperating income, FY2024: −42.03M USDOperating income, FY2025: −26.58M USDNet income, FY2021: −28.3M USDNet income, FY2022: −35.71M USDNet income, FY2023: −29.49M USDNet income, FY2024: −41.84M USDNet income, FY2025: −26.26M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −26.99M USD. Operating income FY2022 −34.64M USD. Operating income FY2023 −29.16M USD. Operating income FY2024 −42.03M USD. Operating income FY2025 −26.58M USD. Net income FY2021 −28.3M USD. Net income FY2022 −35.71M USD. Net income FY2023 −29.49M USD. Net income FY2024 −41.84M USD. Net income FY2025 −26.26M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Cost of goods sold—389K USD———
Gross profit—−389K USD———
Research and development12.61M USD28.48M USD17.5M USD22.53M USD17.17M USD
Selling, general, and administrative13.97M USD13.55M USD11.66M USD12.11M USD9.82M USD
Operating expenses26.58M USD41.64M USD29.16M USD34.64M USD26.99M USD
Interest income520K USD1.5M USD1.12M USD549K USD1.28K USD
Interest expense207K USD1.32M USD1.45M USD1.62M USD1.28M USD
Depreciation and amortization266K USD389K USD381K USD638K USD374K USD
Operating income−26.58M USD−42.03M USD−29.16M USD−34.64M USD−26.99M USD
Net income−26.26M USD−41.84M USD−29.49M USD−35.71M USD−28.3M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 4 misses, 1 met estimate
Average EPS surprise
-62.81%
11 comparable reports
Latest EPS result
-0.34
Estimate -0.3 · Miss by 13.33%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.24-1.6-2.97-4.33Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MetQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 27, 2025: actual -4.03, estimate -3.12, surprise -29.17%, Miss. Q2 2025, reported May 13, 2025: actual -3.16, estimate -3.71, surprise +14.82%, Beat. Q3 2025, reported Aug 11, 2025: actual -2.07, estimate -3.23, surprise +35.91%, Beat. Q4 2025, reported Nov 5, 2025: actual -0.79, estimate -3.27, surprise +75.84%, Beat. Q1 2026, reported Mar 31, 2026: actual -0.62, estimate -0.62, surprise 0.00%, Met estimate. Q2 2026, reported May 14, 2026: actual -2.53, estimate -0.28, surprise -803.57%, Miss. Q3 2026, reported Aug 13, 2026: actual -0.34, estimate -0.3, surprise -13.33%, Miss. Q4 2026, reported Nov 4, 2026: actual —, estimate -0.35, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

5 ratings
Strong buy00%
Buy480%
Hold120%
Sell00%
Strong sell00%

Recent analyst actions

3 institutions

TPST news

globenewswire.com

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

Executed a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T product candidates, including TPST-4003, a CD7-targeted next-generation in vivo CAR-T, with first patient dosing…

Read source
globenewswire.com

Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T

BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced chimeric antigen receptor T-cell…

Read source
globenewswire.com

Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026

BRISBANE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced chimeric antigen receptor T-cell…

Read source
globenewswire.com

Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

BRISANE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest” or “Tempest Therapeutics”) today announced the appointment of two independent directors, Drake Richey and John Yee,…

Read source
globenewswire.com

Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds

BRISBANE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the “Company”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates…

Read source

Corporate actions

Corporate action history

Stock split

Effective Apr 9, 2025

1:13

Stock split

Effective Jun 28, 2021

1:15

Stock split

Effective Dec 10, 2018

1:15

TPST peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding TPST

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
1.05
Weight
—
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
0.35
Weight
—
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research TPST

research.disclaimer